

22, which may mediate the development of the epidermal hyperplasia and tissue inflammation observed in psoriasis.

There is a need for treatment options for inflammatory diseases, in particular psoriasis, psoriatic arthritis, axial (spinal) spondyloarthritis (ax-SpA), including ankylosing
5 spondylitis and non-radiographic ax-SpA, that lead to favorable outcomes for patients, for example in terms of efficacy, safety and/or tolerability of the treatment.

Summary

The present disclosure addresses the above needs and provides methods for treating
10 inflammatory diseases, in particular methods comprising administering an anti-IL-23A antibody to a patient in certain amounts and/or at certain intervals. The present disclosure relates to a method for the treatment of psoriasis or psoriatic arthritis. The present disclosure also relates to a method for the treatment of axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis (AS) and non-radiographic
15 ax-SpA. Accordingly, a method of the present disclosure is for the treatment of ankylosing spondylitis (AS) and a method of the present disclosure is for the treatment of non-radiographic ax-SpA.

The methods of the present disclosure provide the advantage of enabling patients to
20 experience clinical improvement while receiving fewer administrations of the anti-IL-23A antibody.

In one aspect, the present disclosure provides use of an anti-IL-23A antibody in the manufacture of a medicament for the treatment of psoriasis or psoriatic arthritis in a patient, wherein:

- a) an initial dose of said anti-IL-23A antibody is to be administered to the patient;
- b) a first maintenance dose of said anti-IL-23A antibody is to be administered to the patient 4 to 24 weeks, for example 4 to 12 weeks, for example 6 to 24 weeks, for example 6 to 12 weeks after administration of said initial dose; and
- c) at least one additional maintenance dose is to be administered to the patient 4 to 24 weeks, for example 4 to 12 weeks, for example 6 to 24 weeks, for example 6 to 12 weeks, after administration of said first maintenance dose.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 4 to 24 weeks, for example 4 to 16 weeks, for example 4 to 12 weeks, after said initial dose is administered; and

- c) administering at least one additional maintenance dose to the patient 4 to 24 weeks, for example 4 to 16 weeks, for example 4 to 12 weeks, after said first maintenance dose is administered.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method

5 comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 8 to 24 weeks, for example 8 to 16 weeks, for example 8 to 12 weeks, for example 6 to 24 weeks, for example 6 to 16 weeks, for example 6 to 12 weeks, after said initial dose is administered; and
- c) administering at least one additional maintenance dose to the patient 8 to 24 weeks, for example 8 to 16 weeks, for example 8 to 12 weeks, for example 6 to 24 weeks, for example 6 to 16 weeks, for example 6 to 12 weeks, after said first maintenance dose is administered.

In one embodiment, the first maintenance dose is administered to the patient 4, 6, 8, 12, 16, 20 or 24 weeks after the initial dose is administered.

In one embodiment, the at least one additional maintenance dose is administered to the patient 4, 6, 8, 12, 16, 20 or 24 weeks after the first maintenance dose is administered.

In one embodiment, the first maintenance dose is administered to the patient 4, 6, 8, 12, 16, 20 or 24 weeks after the initial dose is administered and the at least one additional maintenance dose is administered to the patient 4, 6, 8, 12, 16, 20 or 24 weeks after the first maintenance dose is administered.

In additional embodiments:

embodiment, in any one of the methods above, the initial dose, the first maintenance dose and the at least one additional maintenance dose comprise 75 mg of the anti- IL-23A antibody.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method

5 comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 12 weeks after said initial dose is administered; and
- c) administering at least one additional maintenance dose to the patient 12 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody. In one embodiment, in said method, the initial dose and the maintenance dose comprise 75 mg of said anti-IL-23A antibody.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method

10 comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 8 weeks after said initial dose is administered; and
- c) administering at least one additional maintenance dose to the patient 8 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose and the maintenance dose comprise 90 mg of said anti-IL-23A antibody. In one embodiment, in said method, the initial dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 16 weeks after said initial dose is administered; and
- c) administering at least one additional maintenance dose to the patient 16 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 6 weeks after said initial dose is administered; and
- c) administering at least one additional maintenance dose to the patient 6 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method

5 comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 4 weeks after said initial dose is administered; and
- c) administering at least one additional maintenance dose to the patient 4 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In another aspect, the present disclosure provides use of an anti-IL-23A antibody in the manufacture of a medicament for the treatment of psoriasis or psoriatic arthritis in a patient, wherein:

- a) an initial dose of said anti-IL-23A antibody is to be administered to the patient;
- b) a loading dose of said anti-IL-23A antibody is to be administered to the patient 1 to 6 weeks after administration of said initial dose;
- c) a first maintenance dose of said anti-IL-23A antibody is to be administered to the patient 6 to 24 weeks, for example 6 to 12 weeks, after administration of said loading dose; and
- d) at least one additional maintenance dose is to be administered to the patient 6 to 24 weeks, for example 6 to 12 weeks, after administration of said first maintenance dose.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of said anti-IL-23A antibody to the patient;
- b) administering a loading dose of said anti-IL-23A antibody to the patient 1 to 6 weeks after said initial dose is administered;
- c) administering a first maintenance dose of said anti-IL-23A antibody to the patient 8 to 24 weeks, for example 8 to 16 weeks, for example 8 to 12 weeks, for example 6 to 24 weeks, for example 6 to 16 weeks, for example 6 to 12 weeks, after said loading dose is administered; and
- d) administering at least one additional maintenance dose to the patient 8 to 24 weeks, for example 8 to 16 weeks, for example 8 to 12 weeks, for example 6 to 24 weeks, for example 6 to 16 weeks, for example 6 to 12 weeks, after said first maintenance dose is administered.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of said anti-IL-23A antibody to the patient;
- b) administering a loading dose of said anti-IL-23A antibody to the patient 4 weeks after said initial dose is administered;
- c) administering a first maintenance dose of said anti-IL-23A antibody to the patient 12 weeks after said loading dose is administered; and
- d) administering at least one additional maintenance dose to the patient 12 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose, the loading dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody. In one embodiment, in said method, the initial dose and the loading dose comprise 300 mg of said anti-IL-23A antibody and the maintenance dose comprises 150 mg of said anti-IL-23A antibody. In one embodiment, in said method, the initial dose and the loading dose comprise 180 mg of said anti-IL-23A antibody and the maintenance dose comprises 90 mg of said anti-IL-23A antibody. In one embodiment, in said method, the initial dose, the loading dose and the maintenance dose comprise 75 mg of said anti-IL-23A antibody.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of said anti-IL-23A antibody to the patient;
- b) administering a loading dose of said anti-IL-23A antibody to the patient 4 weeks after said initial dose is administered;

- c) administering a first maintenance dose of said anti-IL-23A antibody to the patient 8 weeks after said loading dose is administered; and
- d) administering at least one additional maintenance dose to the patient 8 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose, the loading dose and the maintenance dose comprise 90 mg of said anti-IL-23A antibody. In one embodiment, in said method, the initial dose, the loading dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of said anti-IL-23A antibody to the patient;
- b) administering a loading dose of said anti-IL-23A antibody to the patient 4 weeks after said initial dose is administered;
- c) administering a first maintenance dose of said anti-IL-23A antibody to the patient 16 weeks after said loading dose is administered; and
- d) administering at least one additional maintenance dose to the patient 16 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose, the loading dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of said anti-IL-23A antibody to the patient;
- b) administering a loading dose of said anti-IL-23A antibody to the patient 4 weeks after said initial dose is administered;
- c) administering a first maintenance dose of said anti-IL-23A antibody to the patient 6 weeks after said loading dose is administered; and
- d) administering at least one additional maintenance dose to the patient 6 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose, the loading dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In another aspect, the present disclosure provides use of an anti-IL-23A antibody in the manufacture of a medicament for the treatment of psoriasis or psoriatic arthritis, wherein the medicament comprises 15 to 300 mg of the anti-IL-23A antibody.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease comprising administering to a patient 15 to 300 mg, for example 15 to 250 mg, for example 90 to 180 mg, of an anti-IL-23A antibody. In one embodiment, the inflammatory disease is psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA.

In one embodiment, the method comprises administering to a patient 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg, 230 to 250 mg, 240 to 260 mg, 250 to 270 mg, 260 to 280 mg, 270 to 290 mg or 280 to 300 mg of an anti-IL-23A antibody.

In one embodiment, the method comprises administering to a patient 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 mg of an anti-IL-23A antibody. In one embodiment, the method comprises administering to a patient 75 mg of an anti-IL-23A antibody.

In one embodiment, the anti-IL-23A antibody is administered as an an initial dose, a loading dose or a maintenance dose.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease, for treating psoriasis or psoriatic arthritis, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of said anti-IL-23A antibody to the patient; and
- b) administering a second dose of said anti-IL-23A antibody to the patient when the patient no longer maintains a certain PASI score, for example PASI 90, PASI 75, PASI 100 or PASI 50.

In the disclosure, the initial dose and the second dose are doses as described herein.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease, for treating psoriasis or psoriatic arthritis, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of said anti-IL-23A antibody to the patient;
- b) administering a loading dose of said anti-IL-23A antibody to the patient 1 to 6 weeks, for example 4 weeks, after said initial dose is administered; and
- c) administering a third dose of said anti-IL-23A antibody to the patient when the patient no longer maintains a certain PASI score, for example PASI 90, PASI 75, PASI 100 or PASI 50.

In the disclosure, the initial dose, the loading dose and the third dose are doses as described herein.

In one embodiment, in any one of the methods above, the anti-IL-23A antibody is Antibody A, Antibody B, Antibody C or Antibody D.

In one embodiment, in any one of the methods above, the method is for treating plaque psoriasis, for example chronic plaque psoriasis.

Claims

1. Use of an anti-IL-23A antibody in the manufacture of a medicament for the treatment of psoriasis or psoriatic arthritis in a patient, wherein:
 - a) an initial dose of said anti-IL-23A antibody is to be administered to the patient;
 - b) a first maintenance dose of said anti-IL-23A antibody is to be administered to the patient 4 to 24 weeks, for example 4 to 12 weeks, for example 6 to 24 weeks, for example 6 to 12 weeks after administration of said initial dose; and
 - c) at least one additional maintenance dose is to be administered to the patient 4 to 24 weeks, for example 4 to 12 weeks, for example 6 to 24 weeks, for example 6 to 12 weeks, after administration of said first maintenance dose.
2. The use according to claim 1, wherein:
 - a) an initial dose of said anti-IL-23A antibody is to be administered to the patient;
 - b) a first maintenance dose of said anti-IL-23A antibody is to be administered to the patient 8 to 24 weeks, for example 8 to 12 weeks, after administration of said initial dose; and
 - c) at least one additional maintenance dose is to be administered to the patient 8 to 24 weeks, for example 8 to 12 weeks, after administration of said first maintenance dose.
3. The use according to claim 1, wherein said first maintenance dose is to be administered to the patient 8, 12, 16, 20 or 24 weeks after administration of said initial dose.

4. The use according to claim 1, wherein said at least one additional maintenance dose is administered to the patient 8, 12, 16, 20 or 24 weeks after said first maintenance dose is administered.
5. The use according to claim 1, wherein said first maintenance dose is to be administered to the patient 8, 12, 16, 20 or 24 weeks after administration of said initial dose

and said at least one additional maintenance dose is to be administered to the patient 8, 12, 16, 20 or 24 weeks after administration of said first maintenance dose.

6. The use according to claim 1, wherein:

- i. said first maintenance dose is to be administered to the patient 8 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 8 weeks after administration of said first maintenance dose; or
- ii. said first maintenance dose is to be administered to the patient 12 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 12 weeks after administration of said first maintenance dose; or
- iii. said first maintenance dose is to be administered to the patient 16 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 16 weeks after administration of said first maintenance dose; or
- iv. said first maintenance dose is to be administered to the patient 20 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 20 weeks after administration of said first maintenance dose; or
- v. said first maintenance dose is to be administered to the patient 24 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 24 weeks after administration of said first maintenance dose.

7. The use according to claim 1, wherein:

- i. said first maintenance dose is to be administered to the patient 4 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 4 weeks after administration of said first maintenance dose; or

- ii. said first maintenance dose is to be administered to the patient 6 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 6 weeks after administration of said first maintenance dose.
8. The use according to any one of claims 1 to 7, wherein said initial dose comprises 15 to 300 mg of said anti- IL-23A antibody.
9. The use according to any one of claims 1 to 7, wherein said first maintenance dose and said at least one additional maintenance dose comprise 15 to 300 mg of said anti- IL-23A antibody.
10. The use according to any one of claims 1 to 7, wherein said initial dose comprises 15 to 250 mg, for example 90 to 180 mg, of said anti- IL-23A antibody.
11. The use according to any one of claims 1 to 7, wherein said first maintenance dose and said at least one additional maintenance dose comprise 15 to 250 mg, for example 90 to 180 mg, of said anti- IL-23A antibody.
12. The use according to any one of claims 1 to 7, wherein said initial dose comprises 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg or 230 to 250 mg of said anti- IL-23A antibody.
13. The use according to any one of claims 1 to 7, wherein said first maintenance dose and said at least one additional maintenance dose comprise 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg or 230 to 250 mg of said anti- IL-23A antibody.

14. The use according to any one of claims 1 to 7, wherein said initial dose comprises 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti- IL-23A antibody.
15. The use according to any one of claims 1 to 7, wherein said first maintenance dose and said at least one additional maintenance dose comprise 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti- IL-23A antibody.
16. The use according to any one of claims 1 to 7, wherein said initial dose, said first maintenance dose and said at least one additional maintenance dose comprise 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti- IL-23A antibody.
17. Use of an anti-IL-23A antibody in the manufacture of a medicament for the treatment of treating psoriasis or psoriatic arthritis in a patient, wherein:
 - a) an initial dose of said anti-IL-23A antibody is to be administered to the patient;
 - b) a loading dose of said anti-IL-23A antibody is to be administered to the patient 1 to 6 weeks after administration of said initial dose;
 - c) a first maintenance dose of said anti-IL-23A antibody is to be administered to the patient 6 to 24 weeks, for example 6 to 12 weeks, after administration of said loading dose; and
 - d) at least one additional maintenance dose is to be administered to the patient 6 to 24 weeks, for example 6 to 12 weeks, after administration of said first maintenance dose.

18. The use according to claim 17, wherein:

- a) an initial dose of said anti-IL-23A antibody is to be administered to the patient;
- b) a loading dose of said anti-IL-23A antibody is to be administered to the patient
1 to 6 weeks after administration of said initial dose;

- c) a first maintenance dose of said anti-IL-23A antibody is to be administered to the patient 8 to 24 weeks, for example 8 to 12 weeks, after administration of said loading dose; and
- d) at least one additional maintenance dose is to be administered to the patient 8 to 24 weeks, for example 8 to 12 weeks, after administration of said first maintenance dose.

19. The use according to claim 17, wherein said loading dose is to be administered to the patient 1, 2, 3, 4, 5 or 6 weeks after administration of said initial dose.

20. The use according to claim 17 or 19, wherein said first maintenance dose is to be administered to the patient 8, 12, 16, 20 or 24 weeks after administration of said loading dose.

21. The use according to claim 17 or 19, wherein said at least one additional maintenance dose is to be administered to the patient 8, 12, 16, 20 or 24 weeks after administration of said first maintenance dose.

22. The use according to claim 17 or 19, wherein said first maintenance dose is to be administered to the patient 8, 12, 16, 20 or 24 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 8, 12, 16, 20 or 24 weeks after administration of said first maintenance dose.

23. The use according to claim 17 or 19, wherein:

- i. said first maintenance dose is to be administered to the patient 8 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 8 weeks after administration of said first maintenance dose; or
- ii. said first maintenance dose is to be administered to the patient 12 weeks after administration of said initial dose and said at least one additional

maintenance dose is to be administered to the patient 12 weeks after administration of said first maintenance dose; or

- i. said first maintenance dose is to be administered to the patient 16 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 16 weeks after administration of said first maintenance dose; or
- ii. said first maintenance dose is to be administered to the patient 20 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 20 weeks after administration of said first maintenance dose; or
- iii. said first maintenance dose is to be administered to the patient 24 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 24 weeks after administration of said first maintenance dose.

24. The use according to claim 17 or 19, wherein:

- i. said first maintenance dose is to be administered to the patient 6 weeks after administration of said initial dose and said at least one additional maintenance dose is to be administered to the patient 6 weeks after administration of said first maintenance dose.

25. The use according to any one of claims 17 to 24, wherein said initial dose comprises 15 to 300 mg of said anti- IL-23A antibody.

26. The use according to any one of claims 17 to 24, wherein said loading dose comprises 15 to 300 mg of said anti- IL-23A antibody.

27. The use according to any one of claims 17 to 24, wherein said first maintenance dose and said at least one additional maintenance dose comprise 15 to 300 m of said anti- IL-23A antibody.

28. The use according to any one of claims 17 to 24, wherein said initial dose comprises 15 to 250 mg, for example 90 to 180 mg, of said anti- IL-23A antibody.
29. The use according to any one of claims 17 to 24, wherein said loading dose comprises 15 to 250 mg, for example 90 to 180 mg, of said anti- IL-23A antibody.
30. The use according to any one of claims 17 to 24, wherein said first maintenance dose and said at least one additional maintenance dose comprise 15 to 250 mg, for example 90 to 180 mg, of said anti- IL-23A antibody.
31. The use according to any one of claims 17 to 24, wherein said initial dose comprises 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg or 230 to 250 mg of said anti- IL-23A antibody.
32. The use according to any one of claims 17 to 24, wherein said loading dose comprises 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg or 230 to 250 mg of said anti- IL-23A antibody.
33. The use according to any one of claims 17 to 24, wherein said first maintenance dose and said at least one additional maintenance dose comprise 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg or 230 to 250 mg of said anti- IL-23A antibody.

34. The use according to any one of claims 17 to 24, wherein said initial dose comprises 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti-IL-23A antibody.
35. The use according to any one of claims 17 to 24, wherein said first maintenance dose and said at least one additional maintenance dose comprise 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti-IL-23A antibody.
36. The use according to any one of claims 17 to 24, wherein said initial dose and said loading dose comprise 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti-IL-23A antibody.
37. The use according to any one of claims 17 to 24, wherein said initial dose, said loading dose, said first maintenance dose and said at least one additional maintenance dose comprise 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti-IL-23A antibody.
38. Use of an anti-IL-23A antibody in the manufacture of a medicament for the treatment of psoriasis or psoriatic arthritis, wherein said medicament comprises 15 to 300 mg of said anti-IL-23A antibody.
39. The use according to claim 38, wherein said medicament comprises 15 to 250 mg, for example 90 to 180 mg, of said anti-IL-23A antibody.

40. The use according to claim 39, wherein said medicament comprises 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg or 230 to 250 mg of said anti-IL-23A antibody.

41. The use according to claim 30 wherein said medicament comprises 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 mg of said anti-IL-23A antibody.
42. The use according to any one of claims 38 to 41, wherein said anti-IL-23A antibody is to be administered as an an initial dose, a loading dose or a maintenance dose.
43. The use according to anyone of claims 1 to 42, wherein said anti-IL-23A antibody is Antibody A, Antibody B, Antibody C or Antibody D.
44. The use according to anyone of claims 1 to 43, wherein said psoriasis is moderate to severe chronic plaque psoriasis.
45. The use according to any one of claims 1 to 44, wherein said anti-IL-23A antibody is to be administered by subcutaneous administration.